Member Login

              Click here if you forgot your password.

Current Events

Qualified Person Education Course Module A PLUS IMP Pre-Course Session

4-6 June 2024
Munich, Germany

EQPA Members Area

IMP Working Group Members Area

Document and track your personal development - with the Continuous Professional Development (CPD) Documentation Template

To access the template for documenting and tracking your past and ongoing activities, please go here.

After filling out the form, you will be able to create and print out a PDF file.

QPA News

<< Back to overview

19 December 2014

European QP Association announces extension of its Advisory Board

The European QP Association, the voice of more than 2.300 Qualified Persons (QPs) and professionals in similar functions from across Europe and beyond, has announced that it will extend its Advisory Board. At the present time the Board comprises four members from the industry side and two members representing the authority side. It is with great pleasure that we can announce that Dr Rainer Gnibl from the District Government of Upper Franconia, Germany, will now join the Board, increasing the number of regulators to three.

Dr Gnibl has been GMP Inspector for several District Governments of Bavaria as well as EMA-GMP Inspector since 2003. In the agency he focuses on APIs and MPs. He is also head of the national EFG 2 „Inspections/GMP Guide“ Pharmaceutical Supervision Commission and examiner for the 3. State Examination. In addition he holds a lectureship at the Friedrich-Alexander University Erlangen-Nuremberg for „Specific Fields of Law for Pharmacists“.

“We very much look forward to working with Rainer in the future.” said Richard M. Bonner, QP Association Advisory Board Chairman. “With his professional history on the regulator’s side he will be a very valuable addition for our activities to come.” “I am looking forward to be part of the Board,” Dr Rainer Gnibl stated upon his nomination. “In our daily work I can see that much more harmonisation is needed in the pharma world, what – also from a regulator’s point of view – would make things much easier.”

<< Back to overview